U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H19ClN4O5.ClH
Molecular Weight 491.3247
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIVOZANIB HYDROCHLORIDE ANHYDROUS

SMILES

Cc1cc(=NC(=Nc2ccc(cc2Cl)Oc3ccnc4cc(c(cc43)OC)OC)O)[nH]o1.Cl

InChI

InChIKey=NVOQFPILSQNESS-UHFFFAOYSA-N
InChI=1S/C22H19ClN4O5.ClH/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18;/h4-11H,1-3H3,(H2,25,26,27,28);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H19ClN4O5
Molecular Weight 454.8638
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/23788831

Tivozanib (formerly AV-951, KRN-951) is a potent and selective VEGFR tyrosine kinase inhibitor and inhibits angiogenesis and vascular permeability in tumor tissues. It completed phase III a trial investigation for the treatment of renal cell carcinomas, but has not been still approved. In addition, this drug is in the phase II of clinical trial for the investigation it in patients with glioblastoma and colorectal carcinoma.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions
PubMed

PubMed

TitleDatePubMed
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
2006 Sep 15
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.
2008 Mar
Patents

Sample Use Guides

Advanced Renal Cell Carcinoma: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Route of Administration: Oral
KRN951 (TIVOZANIB) potently inhibited VEGF-induced VEGFR-2 phosphorylation in endothelial cells at in vitro subnanomolar IC50 values (IC50 = 0.16 nmol/L). It also inhibited ligand-induced phosphorylation of platelet-derived growth factor receptor-beta (PDGFR-beta) and c-Kit (IC50 = 1.72 and 1.63 nmol/L, respectively). KRN951 blocked VEGF-dependent, but not VEGF-independent, activation of mitogen-activated protein kinases and proliferation of endothelial cells. In addition, it inhibited VEGF-mediated migration of human umbilical vein endothelial cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:03:57 UTC 2021
Edited
by admin
on Sat Jun 26 07:03:57 UTC 2021
Record UNII
Z0UE3Z0EK7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIVOZANIB HYDROCHLORIDE ANHYDROUS
Common Name English
UREA, N-(2-CHLORO-4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(5-METHYL-3-ISOXAZOLYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
Z0UE3Z0EK7
Created by admin on Sat Jun 26 07:03:57 UTC 2021 , Edited by admin on Sat Jun 26 07:03:57 UTC 2021
PRIMARY
PUBCHEM
21079505
Created by admin on Sat Jun 26 07:03:57 UTC 2021 , Edited by admin on Sat Jun 26 07:03:57 UTC 2021
PRIMARY
EPA CompTox
682745-43-3
Created by admin on Sat Jun 26 07:03:57 UTC 2021 , Edited by admin on Sat Jun 26 07:03:57 UTC 2021
PRIMARY
CAS
682745-43-3
Created by admin on Sat Jun 26 07:03:57 UTC 2021 , Edited by admin on Sat Jun 26 07:03:57 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY